Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma

International Journal of Nanomedicine

Volumn 9, Issue , 2014, Pages 5683-5700

  Li, Ying ^a   Yuan, Jiani ^a   Yang, Qian ^a   Cao, Wei ^a   Zhou, Xuanxuan ^a   Xie, Yanhua ^a   Tu, Honghai ^b   Zhang, Ya ^a   Wang, Siwang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Institute for Drug and Instrument Control of PLA   (China)

Author keywords

Anti CD40; Bufalin; Chemoimmunotherapy; Liposomes

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BUFALIN; CASPASE 3; CASPASE 9; CD40 LIGAND MONOCLONAL ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY BUFALIN CONJUGATE; CYTOCHROME C; DNA NUCLEOTIDYLEXOTRANSFERASE; FLUORESCEIN; GAMMA INTERFERON; IMMUNOLIPOSOME; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BUFADIENOLIDE DERIVATIVE; CD40 ANTIGEN; LIPOSOME; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SYNTHESIS; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC50; IMMUNOFLUORESCENCE; IN VITRO STUDY; INFANT; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PARTICLE SIZE; SIDE EFFECT; TRANSMISSION ELECTRON MICROSCOPY; TUMOR LOCALIZATION; TUMOR VOLUME; TUNEL ASSAY; WESTERN BLOTTING; ZETA POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; METABOLISM; PATHOLOGY; SPLEEN; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; APOPTOSIS; BIOMARKERS; BUFANOLIDES; CELL SURVIVAL; FEMALE; LIPOSOMES; MELANOMA; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; SPLEEN; TISSUE DISTRIBUTION;

EID: 84937605931     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S73651     Document Type: Article

References (46)

1. Xie CM, Chan WY, Yu S, Zhao J, Cheng CH. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med. 2011;51(7):1365–1375.
2. Hsu CM, Tsai Y, Wan L, Tsai FJ. Bufalin induces G2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells. Int J Oncol. 2013;43(1):338–348.
3. Tian X, Luo Y, Ya n YB, Sui CG, Meng FD, Liu YP. Effect of bufalin on cellular proliferation and apoptosis in human esophageal squamous carcinoma EC9706 cells. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2012;34(6):556–562. Chinese.
4. Xie XB, Yin JQ, Wen LL, et al. Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research. PLoS One. 2012;7(10):e47375.
5. Pan S, Wang Y, Feng L, et al. Study on proteomics of Hela cell apoptosis in bufalin-induced human cervical carcinoma. Zhongguo Zhong Yao Za Zhi. 2012;37(13):1998–2004. Chinese.
6. Tsai SC, Lu CC, Lee CY, et al. AKT serine/threonine protein kinase modulates bufalin-triggered intrinsic pathway of apoptosis in CAL 27 human oral cancer cells. Int J Oncol. 2012;41(5):1683–1692.
7. Ya n S, Qu X, Xu C, et al. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. J Cancer Res Clin Oncol. 2012;138(8):1279–1289.
8. Huang WW, Yang JS, Pai SJ, et al. Bufalin induces G(0)/G(1) phase arrest through inhibiting the levels of cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells. Mutat Res. 2012;732(1–2):26–33.
9. Jiang Y, Zhang Y, Luan J, et al. Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology. 2010;62(6):573–583.
10. Li D, Qu X, Hou K, et al. PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs. 2009;20(1): 59–64.
11. Zhang Y, Tang X, Liu X, Li F, Lin X. Simultaneous determination of three bufadienolides in rat plasma after intravenous administration of bufadienolides extract by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chim Acta. 2008;610(2):224–231.
12. Qi F, Li A, Inagaki Y, et al. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol. 2011;11(3):342–349.
13. Nesher M, Shpolansky U, Rosen H, Lichtstein D. The digitalis-like steroid hormones: new mechanisms of action and biological signifcance. Life Sci. 2007;80(23):2093–2107.
14. Zhang HQ, Yin ZF, Sheng JY, Jiang ZQ, Wu BY, Su YH. A comparison study of pharmacokinetics between bufalin-loaded bovine serum albumin nanoparticles and bufalin in rats. Zhong Xi Yi Jie He Xue Bao. 2012;10(6):674–680. Chinese.
15. Riker AI, Sondak VK, Fishman M, Daud A, Pilon-Thomas S. Current immunotherapy of melanoma. Clin Appl Immunol Rev. 2005;5(2): 111–132.
16. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol. 2003;13(6):401–407.
17. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84(4):1155–1228.
18. Slominski AT, Carlson JA. Melanoma resistance: a bright future for academicians and a challenge for patient advocates. Mayo Clin Proc. 2014;89(4):429–433.
19. Kiran KL, Lakshminarayanan S. Optimization of chemotherapy and immu-notherapy: in silico analysis using pharmacokinetic–pharmacodynamic and tumor growth models. J Process Control. 2013;23(3): 396–403.
20. Alderson KL, Luangrath M, Elsenheimer MM, et al. Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG. Cancer Immunol Immunother. 2013;62(4):665–675.
21. Frazier JL, Han JE, Lim M, Olivi A. Immunotherapy combined with chemotherapy in the treatment of tumors. Neurosurg Clin N Am. 2010; 21(1):187–194.
22. Khalil M, Vonderheide RH. Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther. 2007;2(2):61–65.
23. Zhang B, Wu T, Chen M, Zhou Y, Yi D, Guo R. The CD40/CD40L system: a new therapeutic target for disease. Immunol Lett. 2013;153(1–2): 58–61.
24. Qu X, Felder MAR, Perez Horta Z, Sondel PM, Rakhmilevich AL. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. Int Immunopharmacol. 2013;17(4):1141–1147.
25. Kwong B, Liu H, Irvine DJ. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials. 2011;32(22):5134–5147.
26. Luo LM, Huang Y, Zhao BX, et al. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modifed liposomes containing paclitaxel. Biomaterials. 2013;34(4):1102–1114.
27. Li F, Weng Y, Wang L, He H, Yang J, Tang X. The effcacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int J Pharm. 2010;393(1–2):203–211.
28. Iyer AK, Su Y, Feng J, et al. The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sar-comatoid mesothelioma. Biomaterials. 2011;32(10):2605–2613.
29. Gao JQ, Lv Q, Li LM, et al. Glioma targeting and blood–brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials. 2013;34(22):5628–5639.
30. Arranz A, Reinsch C, Papadakis KA, et al. Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J Control Release. 2013;165(3):163–172.
31. Broos S, Sandin LC, Apel J, et al. Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles. Biomaterials. 2012;33(26):6230–6239.
32. Hsiao YP, Yu CS, Yu CC, et al. Triggering apoptotic death of human malignant melanoma a375.s2 cells by bufalin: involvement of caspase cascade-dependent and independent mitochondrial signaling pathways. Evid Based Complement Alternat Med. 2012;2012:591241.
33. Jinturkar KA, Anish C, Kumar MK, Bagchi T, Panda AK, Misra AR. Liposomal formulations of etoposide and docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials. 2012;33(8):2492–2507.
34. Sanki A, Scolyer RA, Thompson JF. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol. 2009;35(3):313–319.
35. Mittendorf EA, Lim SJ, Schacherer CW, et al. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg. 2008;195(3):363–368; discussion 368–369.
36. Zhang L, Yoshida T, Kuroiwa Y. Stimulation of melanin synthesis of B16-F10 mouse melanoma cells by bufalin. Life Sci. 1992;51(1):17–24.
37. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003;63(15):4490–4496.
38. Xie F, Shi Q, Wang Q, et al. CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma. J Neuroim-munol. 2010;222(1–2):62–69.
39. Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004; 4(4):360–367.
40. Yang S, Chen J, Zhao D, Han D, Chen X. Comparative study on preparative methods of DC-Chol/DOPE liposomes and formulation optimization by determining encapsulation effciency. Int J Pharm. 2012;434(1–2):155–160.
41. Abreu AS, Castanheira EM, Queiroz MJ, Ferreira PM, Vale-Silva LA, Pinto E. Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-methoxy-3-(4-methoxyphenyl)-1H-indole-2-carboxylate. Nanoscale Res Lett. 2011;6(1):482.
42. Nestal de Moraes G, Carvalho É, Maia RC, Sternberg C. Immunodetec-tion of caspase-3 by Western blot using glutaraldehyde. Anal Biochem. 2011;415(2):203–205.
43. Giegé P, Grienenberger JM, Bonnard G. Cytochrome c biogenesis in mitochondria. Mitochondrion. 2008;8(1):61–73.
44. Nagase M, Shiota T, Tsushima A, et al. Molecular mechanism of satratoxin-induced apoptosis in HL-60 cells: activation of caspase-8 and caspase-9 is involved in activation of caspase-3. Immunol Lett. 2002;84(1):23–27.
45. Paulis LE, Mandal S, Kreutz M, Figdor CG. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr Opin Immunol. 2013; 25(3):389–395.
46. Costello RT, Gastaut JA, Olive D. What is the real role of CD40 in cancer immunotherapy? Immunol Today. 1999;20(11):488–493.